Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Arvinas Inc
ARVNCurrent price
29.52 USD
+0.67 USD (+2.32%)
Last closed
28.87 USD
Company
www.arvinas.com
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
1 951 677 952 USD
Yield for 12 month
+34.67 %
1Y
3Y
5Y
10Y
15Y
ARVN
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut. Address: 5 Science Park, New Haven, CT, United States, 06511
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
68.44 USDP/E ratio
–Dividend Yield
–Current Year
+78 500 000 USD
Last Year
+131 400 000 USD
Current Quarter
+25 300 000 USD
Last Quarter
-43 100 000 USD
Current Year
+71 800 000 USD
Last Year
+131 400 000 USD
Current Quarter
+23 600 000 USD
Last Quarter
-44 800 000 USD
Key Figures ARVN
1 year
3 years
5 years
10 years
EBITDA
-392 300 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-20.78 %
PEG Ratio
–
Return On Equity TTM
-63.32 %
Wall Street Target Price
68.44 USD
Revenue TTM
71 300 000 USD
Book Value
8.93 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-22.2 %
Dividend Yield
–
Gross Profit TTM
131 400 000 USD
Earnings per share
-6.05 USD
Diluted Eps TTM
-6.05 USD
Most Recent Quarter
I 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics ARVN
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ARVN
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation ARVN
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
17.6991
Enterprise Value Revenue
15.4605
Price Sales TTM
31.4747
Enterprise Value EBITDA
-3.0741
Price Book MRQ
3.7446
Financials ARVN
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators ARVN
For 52 weeks
13.57 USD
53.08 USD
50 Day MA
28.78 USD
Shares Short Prior Month
9 018 706
200 Day MA
33.33 USD
Short Ratio
9.24
Shares Short
9 539 564
Short Percent
14.19 %
BeatStart